Carboxypeptidase G2

• Carboxypeptidase G2 is an enzyme derived from bacteria that specifically breaks down folate and antifolate compounds.
• Its primary clinical application is to rapidly reduce toxic levels of methotrexate, a chemotherapy drug, in patients.
• The enzyme works by hydrolyzing the glutamate residue from methotrexate, rendering it inactive and facilitating its clearance from the body.
• This therapeutic intervention is vital in managing severe methotrexate toxicity, preventing life-threatening complications.

What is Carboxypeptidase G2?

Carboxypeptidase G2 is an enzyme originating from the bacterium Pseudomonas stutzeri, characterized by its ability to hydrolyze the C-terminal glutamate residue from various pteroylglutamate substrates. This enzymatic action specifically targets folates and antifolate compounds, such as the widely used chemotherapy drug methotrexate. Its unique specificity and high catalytic efficiency make it a critical tool in clinical settings, particularly in managing drug toxicity and enhancing patient safety during certain cancer treatments.

The enzyme’s function is distinct from human carboxypeptidases, which typically have broader substrate specificities. Carboxypeptidase G2’s precise action on folates and antifolates allows for targeted intervention without significantly interfering with other crucial biological processes. This specificity is a cornerstone of its therapeutic utility, enabling rapid and effective detoxification when needed.

Mechanism of Carboxypeptidase G2 Action

The carboxypeptidase G2 mechanism involves the zinc-dependent hydrolysis of the amide bond between the pteridine moiety and the glutamate residue of its substrates. Specifically, in the case of methotrexate, Carboxypeptidase G2 cleaves the C-terminal glutamate from the drug molecule. This enzymatic breakdown converts methotrexate into inactive metabolites, 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.

This conversion is irreversible and significantly reduces the pharmacological activity of methotrexate. By rapidly metabolizing the drug, Carboxypeptidase G2 effectively lowers systemic methotrexate concentrations, thereby mitigating its toxic effects on healthy cells. The resulting inactive metabolites are then more readily excreted from the body, primarily through renal pathways, further aiding in detoxification. This rapid enzymatic degradation is crucial for reversing severe drug accumulation.

Clinical Applications and Function of Carboxypeptidase G2

The primary carboxypeptidase G2 function in clinical practice is its use as an antidote for severe methotrexate toxicity. Methotrexate is a potent antifolate agent used in the treatment of various cancers, including acute lymphoblastic leukemia, osteosarcoma, and lymphomas, as well as certain autoimmune diseases. However, high doses or impaired elimination can lead to life-threatening complications such such as myelosuppression, mucositis, and renal failure.

When patients experience dangerously elevated methotrexate levels, often due to delayed clearance or renal dysfunction, Carboxypeptidase G2 is administered intravenously. The enzyme rapidly breaks down methotrexate in the bloodstream, reducing its concentration and preventing further damage to healthy tissues. This immediate reduction in methotrexate levels is critical for patient survival and recovery. The carboxypeptidase G2 uses extend to situations where standard rescue therapies, such as leucovorin, are insufficient or when toxicity is already severe.

According to clinical data, the administration of Carboxypeptidase G2 can lead to a rapid and substantial decrease in plasma methotrexate levels, often within minutes to hours, significantly improving outcomes for patients facing severe toxicity. Its ability to rapidly inactivate methotrexate makes it an indispensable component of rescue protocols in oncology, underscoring its vital role in modern cancer therapy management.